Equity Profile

SMMT

Summit Therapeutics Inc.

Health CareBiotechnology$11.9B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and revenues.

N/A

Revenue Growth

Revenue growth is essential to assess the company's market performance and acceptance of its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing innovative medicines for serious diseases. With a market cap of $12 billion, it operates in the health care sector, which is increasingly important as the demand for advanced therapies grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1 2026, Summit Therapeutics reported an EPS of -$0.15, beating expectations by nearly 55%. The stock reacted positively, increasing by over 3% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to cost management and operational efficiency.
Plans to provide more detailed guidance in future earnings calls.

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with investors keen to see if the company can maintain its positive momentum from the last quarter.

Bull Case

If Summit can report a smaller-than-expected loss and show progress in its clinical trials, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and their expected timelines?

Investors will closely watch for updates that could influence future revenue potential and market confidence.

How does management plan to manage costs moving forward?

Given the company's history of losses, effective cost management will be crucial for improving profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for significant progress in clinical trials, which could lead to higher-than-expected future revenues.

Supporting Evidence

The company's recent EPS surprises indicate a trend of outperforming expectations.

Options pricing suggests a high level of anticipated volatility, which may not align with the current consensus.

Positive investor sentiment from recent trial updates could drive unexpected growth.

Key Risk

If clinical trial results exceed expectations, it could dramatically shift the market's outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the balance between cost management and clinical trial advancements.

Bull Confirmed If

A reported EPS loss of less than $0.10 would confirm the bull case, indicating improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $0.20 would confirm the bear case, suggesting ongoing challenges in managing costs.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests a potential stock increase of around 5.8%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of about 1.4%, reflecting investor disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Details on cost management strategies and their expected impact.
3Any new partnerships or collaborations that could enhance growth prospects.
4Guidance on future revenue expectations and timelines.
5Management's outlook on market conditions and competitive landscape.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Summit Therapeutics Inc. (SMMT) is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability and will indicate how well the company is managing its costs and revenues.

N/A

Revenue Growth

Revenue growth is essential to assess the company's market performance and acceptance of its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1 2026, Summit Therapeutics reported an EPS of -$0.15, beating expectations by nearly 55%. The stock reacted positively, increasing by over 3% the following day.

Management Promises & Guidance

Continued focus on advancing clinical trials.
Commitment to cost management and operational efficiency.
Plans to provide more detailed guidance in future earnings calls.

Expectations

Wall Street Expectations

Overall, expectations are mixed ahead of the earnings report, with investors keen to see if the company can maintain its positive momentum from the last quarter.

Bull Case

If Summit can report a smaller-than-expected loss and show progress in its clinical trials, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing guidance, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and their expected timelines?

Investors will closely watch for updates that could influence future revenue potential and market confidence.

How does management plan to manage costs moving forward?

Given the company's history of losses, effective cost management will be crucial for improving profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for significant progress in clinical trials, which could lead to higher-than-expected future revenues.

Supporting Evidence

The company's recent EPS surprises indicate a trend of outperforming expectations.

Options pricing suggests a high level of anticipated volatility, which may not align with the current consensus.

Positive investor sentiment from recent trial updates could drive unexpected growth.

Key Risk

If clinical trial results exceed expectations, it could dramatically shift the market's outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the balance between cost management and clinical trial advancements.

Bull Confirmed If

A reported EPS loss of less than $0.10 would confirm the bull case, indicating improved operational efficiency.

Bear Confirmed If

An EPS loss greater than $0.20 would confirm the bear case, suggesting ongoing challenges in managing costs.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests a potential stock increase of around 5.8%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of about 1.4%, reflecting investor disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Details on cost management strategies and their expected impact.
3Any new partnerships or collaborations that could enhance growth prospects.
4Guidance on future revenue expectations and timelines.
5Management's outlook on market conditions and competitive landscape.